Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study
-
Published:2023-11-25
Issue:
Volume:
Page:
-
ISSN:0268-3369
-
Container-title:Bone Marrow Transplantation
-
language:en
-
Short-container-title:Bone Marrow Transplant
Author:
Mussetti A., Rius-Sansalvador B.ORCID, Moreno V., Peczynski C.ORCID, Polge E., Galimard J. E.ORCID, Kröger N.ORCID, Blaise D.ORCID, Peffault de Latour R., Kulagin A.ORCID, Mousavi A., Stelljes M., Hamladji R. M., Middeke J. M., Salmenniemi U., Sengeloev H., Forcade E.ORCID, Platzbecker U., Reményi P., Angelucci E., Chevallier P.ORCID, Yakoub-Agha I.ORCID, Craddock C.ORCID, Ciceri F.ORCID, Schroeder T., Aljurf M.ORCID, Ch KoeneckeORCID, Moiseev I.ORCID, Penack O.ORCID, Schoemans H.ORCID, Mohty M.ORCID, Glass B., Sureda A.ORCID, Basak G.ORCID, Peric Z.ORCID
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference33 articles.
1. Cieri N, Maurer K, Wu CJ. 60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy. Cancer Res. 2021;81:4373–84. 2. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant [Internet]. 2022 May [cited 2022 Jul 25]; Available from: https://www.nature.com/articles/s41409-022-01691-w 3. Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Cámara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transpl. 2021;56:1651–64. 4. McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts. Ann Intern Med. 2020;172:229. 5. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.
|
|